Capitol Street Has Been Featured on These News Outlets
The Wall Street Journal
Investors Assumed Medicare Advantage Was Safe Under the GOP. They Were Wrong.
January 28, 2026
Smolinski on the nuanced Medicare Advantage 2027 rate notice as not representing a GOP distaste towards Medicare Advantage, but rather a policy document meant to equalize the playing field between large plans and those that are regional, non-profit, multi-state Blues.
Bloomberg
Unpacking Medicaid Changes in One Big Beautiful Bill
July 2, 2025
Smolinski discussed with Bloomberg TV Capitol Street’s take on: Medicaid & Medicare, the impact on hospitals, sectors spared by reductions (Medicare Advantage, PBM) and next steps/likely final passage of One Big Beautiful Bill this summer.
The Wall Street Journal
Ozempic Among the Next Drugs Up for Medicare Price Negotiations
January 17, 2025
In an article by the Wall Street Journal, Ipsita Smolinski discusses the recent release of the 15 drugs that will be subject to the second round of price negotiations by Medicare, including Ozempic and Wegovy, as the government heads into a new administration.
BioCentury
MFN & International Pricing’s Path Forward for the Trump Administration
May 3, 2025
In an article published in BioCentury, Capitol Street’s Ipsita Smolinski discussed possible ways MFN policies could be implemented. Additionally, she covers provisions in an April Executive Order on drug pricing, and how the EO may affect CMS, CMMI, and MFN policies.
Inside Health Policy
Medicaid Plans Ramp Up Warnings On Pay Rates, Mismatch Post-PHE
October 21, 2024
In an from Inside Health Policy, Smolinski offered insights on the rate and acuity mismatch – stating the pressure on Medicaid costs resulting from the acuity shift is not surprising – but perhaps the magnitude is. She also points out Medicaid plans have highlighted states’ obligation to provide actuarially sound rates.
BioCentury
Medicaid Drug Price Transparency
May 24, 2023
Smolinski was interviewed about the CMS proposal for a Medicaid drug price name and shame policy. CMS has proposed a new Medicaid rule aimed at increasing transparency around some drug prices and PBM practices. Under the proposal, Medicaid would not be given power over drug prices. Rather, it would create what Capitol Street consultants call a “Medicaid Rx wall of shame” on which it would post the prices of three to 10 drugs Medicaid believes have abnormally high prices or have been subject to large price increases.
JPMorgan Healthcare Conference
JP Morgan keynote discussion with FDA Commissioner Califf and ARPA-H Director Wegrzyn
January 10, 2023
For the Jan. 10 lunchtime keynote at the JP Morgan Healthcare Conference, Ipsita Smolinski of Capitol Street and Rachel Vatnsdal of JP Morgan co-host a discussion with FDA Commissioner Robert Califf and ARPA-H Director Renee Wegrzyn about the Biden Administration’s 2023 priorities for Life Sciences, BioPharma and MedTech.
Modern Healthcare
Planning for Fiscal Strength in Changing Times
June 23, 2021
During a June 23 virtual event presented by Allscripts and Modern Healthcare Custom Media, Ipsita Smolinski, Managing Partner of Capitol Street Research and Senior Strategic Adviser at McAllister & Quinn, and Richard Mulry, President and CEO of Northwell Holdings and Ventures, offered insights into and guidance specific to where hospital systems should be prioritizing as they do strategic planning, during a COVID time of health equity and physician employment along with increasing transparency rules for health systems, looking ahead to the next several years.
Recent Media Appearances
